PMV Pharma raises $50m and readies first FDA filing for rezatapopt

PMV Pharmaceuticals has set out a route to market for its lead asset, rezatapopt, and has topped up its funds to get there. On 10 November 2026 the US biotech said it would file a new drug application with the Food and Drug Administration in the first quarter of 2027, asking for accelerated approval in ovarian cancer driven by a TP53 Y220C mutation. The target population is patients whose disease has resisted platinum-based therapy or stopped responding to it.

The filing plan draws on interim results from the Phase 2 PYNNACLE study. Among 76 patients, 46% responded to treatment. The company also reported that 5% of patients stopped treatment because of side effects linked to the drug. The data summary supplied does not break down response durability, trial design or safety events further, so the strength of the package remains unclear. PMV will present full results from the pivotal cohort at ENA 2026.

On the financing side, PMV reported $108.5 million in cash in its third-quarter update. It has since completed a $50 million public offering and now expects its resources to last into the first quarter of 2028. That timeline would cover the planned submission and the period in which the agency reviews it. The facts provided do not state how much of the cash is earmarked for launch preparation or manufacturing, and give no pricing or market-size estimates.

As general context, accelerated approval is a US pathway that can allow authorisation of medicines for serious conditions on the basis of surrogate or intermediate endpoints. It typically comes with a requirement for confirmatory evidence after approval.